Case Commentary: When Voldemort Meets Sauron: Treatment Considerations for Emerging Dual-Carbapenemase-Producing Extensively Drug-Resistant Pseudomonas Aeruginosa

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2023 Jun 13

PMID 37310216

Authors

Walaiporn Wangchinda

Jason M Pogue

Affiliations

Soon will be listed here.

Abstract

Infections caused by extensively drug-resistant Pseudomonas aeruginosa are difficult to treat due to limited effective treatment options. In this issue, a patient with a corneal infection caused by a Verona integron-encoded metallo-β-lactamase (VIM)- and Guiana extended-spectrum β-lactamase (GES)-coproducing P. aeruginosa strain associated with the recent artificial tears-related outbreak in the United States is described. This resistance genotype/phenotype further compromises therapeutic options, and this report provides insights into diagnostic and treatment approaches for clinicians dealing with infections due to this highly resistant P. aeruginosa.

Citing Articles

Nucleus-forming jumbophage PhiKZ therapeutically outcompetes non-nucleus-forming jumbophage Callisto.

Naknaen A, Samernate T, Saeju P, Nonejuie P, Chaikeeratisak V iScience. 2024; 27(5):109790.

PMID: 38726363 PMC: 11079468. DOI: 10.1016/j.isci.2024.109790.

References

Mushtaq S, Meunier D, Vickers A, Woodford N, Livermore D . Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. J Antimicrob Chemother. 2020; 76(2):434-442. DOI: 10.1093/jac/dkaa456. View

Karlowsky J, Lob S, Raddatz J, DePestel D, Young K, Motyl M . In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United.... Clin Infect Dis. 2020; 72(12):2112-2120. DOI: 10.1093/cid/ciaa381. View

Kazmierczak K, Rabine S, Hackel M, McLaughlin R, Biedenbach D, Bouchillon S . Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015; 60(2):1067-78. PMC: 4750703. DOI: 10.1128/AAC.02379-15. View

Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C . Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P..... Clin Infect Dis. 2020; 72(7):e169-e183. DOI: 10.1093/cid/ciaa1478. View

Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo R . European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2021; 28(4):521-547. DOI: 10.1016/j.cmi.2021.11.025. View

Karlowsky J, Kazmierczak K, de Jonge B, Hackel M, Sahm D, Bradford P . Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrob Agents Chemother. 2017; 61(9). PMC: 5571336. DOI: 10.1128/AAC.00472-17. View

Mushtaq S, Sadouki Z, Vickers A, Livermore D, Woodford N . Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2020; 64(12). PMC: 7674041. DOI: 10.1128/AAC.01582-20. View

Ahmed S, Kuruvilla O, Chin Yee D, Aggarwal H, Li Y, Edwards P . Intraocular penetration of systemic antibiotics in eyes with penetrating ocular injury. J Ocul Pharmacol Ther. 2014; 30(10):823-30. DOI: 10.1089/jop.2014.0056. View

Longshaw C, Manissero D, Tsuji M, Echols R, Yamano Y . activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe. JAC Antimicrob Resist. 2021; 2(3):dlaa060. PMC: 8210120. DOI: 10.1093/jacamr/dlaa060. View

10.

Gill C, Aktab E, Alfouzan W, Bourassa L, Brink A, Burnham C . The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021; 40(12):2533-2541. PMC: 8590662. DOI: 10.1007/s10096-021-04308-0. View

11.

Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T . Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000; 44(12):3322-7. PMC: 90200. DOI: 10.1128/AAC.44.12.3322-3327.2000. View

12.

Insler M, Helm C, George W . Topical vs systemic gentamicin penetration into the human cornea and aqueous humor. Arch Ophthalmol. 1987; 105(7):922-4. DOI: 10.1001/archopht.1987.01060070058028. View

13.

Hernandez-Garcia M, Garcia-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C . Activity of Cefepime-Taniborbactam against Carbapenemase-Producing and Pseudomonas aeruginosa Isolates Recovered in Spain. Antimicrob Agents Chemother. 2022; 66(3):e0216121. PMC: 8923209. DOI: 10.1128/aac.02161-21. View

14.

Almarzoky Abuhussain S, Sutherland C, Nicolau D . potency of antipseudomonal β-lactams against blood and respiratory isolates of collected from US hospitals. J Thorac Dis. 2019; 11(5):1896-1902. PMC: 6588753. DOI: 10.21037/jtd.2019.05.13. View

15.

Fernandes M, Vira D, Medikonda R, Kumar N . Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome. Graefes Arch Clin Exp Ophthalmol. 2015; 254(2):315-22. DOI: 10.1007/s00417-015-3208-7. View

16.

Reyes J, Komarow L, Chen L, Ge L, Hanson B, Cober E . Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe. 2023; 4(3):e159-e170. PMC: 10016089. DOI: 10.1016/S2666-5247(22)00329-9. View

17.

Sader H, Castanheira M, Duncan L, Flamm R . Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance.... Diagn Microbiol Infect Dis. 2018; 92(1):69-74. DOI: 10.1016/j.diagmicrobio.2018.04.012. View

18.

Kazmierczak K, Tsuji M, Wise M, Hackel M, Yamano Y, Echols R . In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates.... Int J Antimicrob Agents. 2018; 53(2):177-184. DOI: 10.1016/j.ijantimicag.2018.10.007. View

19.

Hernandez-Garcia M, Garcia-Castillo M, Melo-Cristino J, Pinto M, Goncalves E, Alves V . In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies). J Antimicrob Chemother. 2022; 77(11):3163-3172. DOI: 10.1093/jac/dkac298. View

20.

Le Terrier C, Nordmann P, Poirel L . In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases. J Antimicrob Chemother. 2022; 78(1):101-107. DOI: 10.1093/jac/dkac360. View